stockrowVericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Revenue
- +26.5%
- EPS
- +180.0%
- Free cash flow
- −19.4%
Quarter to September 2026, against a year earlier
Follow VCEL
Alert me
Vericel Corporation (VCEL) Gross margin
Vericel Corporation's gross margin over the twelve months to 30 September 2026 was 74.5%, up 0.1 percentage points from fiscal 2025 (74.4%). Over the past ten years it has ranged from 48.0% (fiscal 2016) to 74.4% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 74.4% | 1.87 |
| FY2024 | 72.6% | 3.91 |
| FY2023 | 68.6% | 1.84 |
| FY2022 | 66.8% | (1.08) |
| FY2021 | 67.9% | 0.05 |
| FY2020 | 67.8% | (0.29) |
| FY2019 | 68.1% | 3.52 |
| FY2018 | 64.6% | 12.08 |
| FY2017 | 52.5% | 4.57 |
| FY2016 | 48.0% | (0.32) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 73.3% | 0.52 |
| Jun 2026 | 72.8% | 0.82 |
| Mar 2026 | 72.0% | (6.70) |
| Dec 2025 | 78.7% | 5.24 |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| IMNM Immunome, Inc. compare | 100.0% |
| CLDX Celldex Therapeutics, Inc. compare | 100.0% |
| PVLA Palvella Therapeutics, Inc. compare | 100.0% |
| AUPH Aurinia Pharmaceuticals Inc compare | 90.6% |
| VCEL Vericel Corporation | 74.5% |
| ADMA ADMA Biologics Inc compare | 68.5% |
| VERA Vera Therapeutics, Inc. compare | 0.00% |
| BHVN Biohaven Ltd. compare | 0.00% |
| PHVS Pharvaris N.V. compare | 0.00% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on VCEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement